Circulating cytokines and angiogenic factors (CAFs) in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: Results from a phase II clinical trial

被引：0
|
作者：
Bilen, Mehmet Asim [1 ]
Zurita, Amado J. [1 ]
Ilias-Khan, Nasreen A. [1 ]
Chen, Hsiang-Chun [1 ]
Wang, Xuemei [1 ]
Hodges, Sherie [1 ]
Lim, Zita D. [1 ]
Jonasch, Eric [1 ]
Khakoo, Aarif Yusuf [1 ]
Tannir, Nizar M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.483
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
483
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
    Tannir, Nizar M.
    Jonasch, Eric
    Albiges, Laurence
    Altinmakas, Emre
    Ng, Chaan S.
    Matin, Surena F.
    Wang, Xuemei
    Wang, Xuemei
    Qiao, Wei
    Lim, Zita Dubauskas
    Tamboli, Pheroze
    Rao, Priya
    Sircar, Kanishka
    Karam, Jose A.
    McDermott, David F.
    Wood, Christopher G.
    Choueiri, Toni K.
    EUROPEAN UROLOGY, 2016, 69 (05) : 866 - 874
  • [42] A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST)
    Ahrens, M.
    Escudier, B.
    Haanen, J.
    Gross-Goupil, M.
    Boleti, E.
    Gravis, G.
    Grimm, M. -O.
    Negrier, S.
    Bedke, J.
    Barthelemy, P.
    Castellano, D.
    Mellado, B.
    Ivanyi, P.
    Rottey, S.
    Florcken, A.
    Maroto, J. P.
    Rodriguez, Suarez C.
    Oosting, S. F.
    Panic, A.
    Zschabitz, S.
    Boegemann, M.
    Kopecky, J.
    Deckbar, D.
    Hartmann, A.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 317 - 318
  • [43] Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
    Tykodi, Scott S.
    Gordan, Lucio N.
    Alter, Robert S.
    Arrowsmith, Edward
    Harrison, Michael R.
    Percent, Ivor
    Singal, Rakesh
    Van Veldhuizen, Peter
    George, Daniel J.
    Hutson, Thomas
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Kalebasty, Arash Rezazadeh
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [44] Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.
    Tannir, Nizar M.
    Jonasch, Eric
    Altinmakas, Emre
    Ng, Chaan S.
    Qiao, Wei
    Tamboli, Pheroze
    Rao, Priya
    McDermott, David F.
    Wood, Christopher G.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma A Secondary Analysis of a Randomized Clinical Trial
    Gulati, Shuchi
    Tangen, Catherine
    Ryan, Christopher W.
    Vaishampayan, Ulka N.
    Shuch, Brian M.
    Barata, Pedro C.
    Pruthi, Deepak K.
    Bergerot, Cristiane D.
    Tripathi, Abhishek
    Lerner, Seth P.
    Thompson, Ian M.
    Lara, Primo N.
    Pal, Sumanta K.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [46] Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.
    Yildiz, Ibrahim
    Ekenel, Meltem
    Altman, Tuley
    Kocar, Muharrem
    Uysal, Mukremin
    Kanitez, Metin
    Bayoglu, Vedat
    Varol, Umut
    Tural, Deniz
    Avcl, Nilufer
    Kaplan, Muhammet All
    Surmeli, Zeki
    Dede, Isa
    Ulas, Arife
    Yazici, Ozan
    Basaran, Mert
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non-Clear Cell Renal Cell Carcinoma
    Rodriguez Faba, Oscar
    Breda, Alberto
    Rosales, Antonio
    Palou, Joan
    Algaba, Ferran
    Maroto Rey, Pablo
    Villavicencio, Humberto
    EUROPEAN UROLOGY, 2010, 58 (02) : 307 - 310
  • [48] PHASE II TRIAL OF NEOADJUVANT AXITINIB IN PATIENTS WITH LOCALLY ADVANCED NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA
    Karam, Jose
    Devine, Catherine
    Urbauer, Diana
    Lozano, Marisa
    Maity, Tapati
    Ahrar, Kamran
    Tamboli, Pheroze
    Tannir, Nizar
    Wood, Christopher
    JOURNAL OF UROLOGY, 2014, 191 (04): : E646 - E646
  • [49] The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)
    Stadler, W. M.
    Figlin, R. A.
    Ernstoff, M. S.
    Curti, B.
    Pendergrass, K.
    Srinivas, S.
    Canfield, V.
    Weissman, C.
    Poulin-Costello, M.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
    Graham, Jeffrey
    Wells, John Connor
    Dudani, Shaan
    Gan, Chun L.
    Donskov, Frede
    Lee, Jae-Lyun
    Kollmannsberger, Christian K.
    Meza, Luis
    Beuselinck, Benoit
    Hansen, Aaron
    North, Scott A.
    Bjarnason, Georg A.
    Sayegh, Nicolas
    Kanesvaran, Ravindran
    Wood, Lori A.
    Hotte, Sebastien J.
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2022, 171 : 124 - 132
12345